<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Genetically engineered stem cells (GESTECs) exhibit a potent therapeutic efficacy via their strong <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> tropism toward <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells </plain></SENT>
<SENT sid="1" pm="."><plain>In this study, we introduced the human parental neural stem cells, HB1.F3, with the human interferon beta (IFN-β) gene which is a typical cytokine gene that has an antitumor effect and the <z:chebi fb="1" ids="16040">cytosine</z:chebi> deaminase (CD) gene from Escherichia coli (E. coli) that could convert the non-toxic <z:chebi fb="0" ids="50266">prodrug</z:chebi>, <z:chebi fb="0" ids="5100">5-fluorocytosine</z:chebi> (<z:chebi fb="0" ids="5100">5-FC</z:chebi>), to a toxic metabolite, <z:chebi fb="0" ids="46345">5-fluorouracil</z:chebi> (5-FU) </plain></SENT>
<SENT sid="2" pm="."><plain>Two types of stem cells expressing the CD gene (HB1.F3.CD cells) and both the CD and human IFN-β genes (HB1.F3.CD.IFN-β) were generated </plain></SENT>
<SENT sid="3" pm="."><plain>The present study was performed to examine the migratory and therapeutic effects of these GESTECs against the <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> cell line, HT-29 </plain></SENT>
<SENT sid="4" pm="."><plain>When co-cultured with <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> cells in the presence of <z:chebi fb="0" ids="5100">5-FC</z:chebi>, HB1.F3.CD and HB1.F3.CD.IFN-β cells exhibited the cytotoxicity on HT-29 cells via the bystander effect </plain></SENT>
<SENT sid="5" pm="."><plain>In particular, HB1.F3.CD.IFN-β cells showed the synergistic cytotoxic activity of 5-FU and IFN-β </plain></SENT>
<SENT sid="6" pm="."><plain>We also confirmed the migration ability of HB1.F3.CD and HB1.F3.CD.IFN-β cells toward HT-29 cells by a modified migration assay in vitro, where chemoattractant factors secreted by HT-29 cells attracted the GESTECs </plain></SENT>
<SENT sid="7" pm="."><plain>In a xenograft mouse model, the volume of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> mass was decreased up to 56% in HB1.F3.CD injected mice while the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> mass was greatly inhibited about 76% in HB1.F3.CD.IFN-β injected mice </plain></SENT>
<SENT sid="8" pm="."><plain>The therapeutic treatment by these GESTECs is a novel strategy where the combination of the migration capacity of stem cells as a vector for therapeutic genes towards <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> and a synergistic antitumor effect of CD and IFN-β genes can selectively target this type of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
</text></document>